Home / Drug Discovery / Ubiquitin Proteasome Market: Global Industry Trends, Market Size, Competitive Analysis and Forecast - 2017 – 2025

Ubiquitin Proteasome Market: Global Industry Trends, Market Size, Competitive Analysis and Forecast - 2017 – 2025

Published: Nov 2017 | Published By: Acute Market Research

The latest published report by Acute Market Research titled Ubiquitin Proteasome Market: Global Industry Trends, Market Size, Competitive Analysis and Forecast - 2017 – 2025, studies the global markets for Ubiquitin Proteasome in terms of product type, technology type,  application type, end-user and regional categorization, major market participants and competitive front for the period 2015 to 2025.

This study on Ubiquitin Proteasome market offers comprehensive analysis with respect to the current geographical trends, market dynamics and country level market size of the Ubiquitin Proteasome industry. The analysis thus performed for the Ubiquitin Proteasome market considers factors such as market definition, market classification, industry trends, competitive landscape of the key participants in the industry, etc. The proposed report presents the market estimates and forecast for the period 2015-2025, along with respective CAGRs for each segment and regional distribution for the period 2017-2025. In addition, assessment of marketing models, profiling of key companies and analysis of market dynamics would give a bird eye view insights to the global Ubiquitin Proteasome market.

Report Scope: Ubiquitin Proteasome Market

This report provides an in-depth assessment of the Ubiquitin Proteasome market presented through sections such as

1.         Ubiquitin Proteasome: Market Overview

2.         Major Commercial Developments in the Ubiquitin Proteasome Industry

3.         Market Trends and Dynamics of Ubiquitin Proteasome Industry

4.         Attractive Investment Proposition for Ubiquitin Proteasome Market

5.         Market Positioning of Key Market Players in Ubiquitin Proteasome Industry

6.         Current Market Scenario and Future Prospects of the Ubiquitin Proteasome Market

7.         Competitive Landscape of the Ubiquitin Proteasome Market

8.         Ubiquitin Proteasome Market Revenue and Forecast, by Product Type, 2015 to 2025

9.         Ubiquitin Proteasome Market Revenue and Forecast, by Technology Type, 2015 to 2025

10.       Ubiquitin Proteasome Market Revenue and Forecast, by Applications Type, 2015 to 2025

11.       Ubiquitin Proteasome Market Revenue and Forecast, by End-User, 2015 to 2025

12.       Ubiquitin Proteasome Market Revenue and Forecast, by Geography, 2015 to 2025

1. Preface
1.1. Report Scope and Description
1.2. Research Methodology

2. Executive Summary
2.1. Ubiquitin Proteasome Market Industry Snapshot

3. Global Ubiquitin Proteasome Market Analysis
3.1. Ubiquitin Proteasome Market Overview: Current and Future Trends
3.2. Market Inclination Insights
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.2. Challenges
3.3.3. Opportunities
3.4. Attractive Investment Proposition, 2015
3.5. Market Positioning of Key Players operating in Ubiquitin Proteasome Industry

4. Global Ubiquitin Proteasome Market, By Type of Application, 2014 – 2022 (US$ Mn)
4.1. Overview
4.2. Drug Discovery
4.2.1. E1 Ligase
4.2.2. E2 Ligase
4.2.3. E3 Ligase
4.2.4. Deubiquitnases
4.3. Diagnosis
4.3.1. Cancer Biomarkers
4.3.2. Cardiovascular Disease Biomarkers
4.3.3. Central Nervous System (CNS) Biomarkers
4.3.4. Others

5. Global Ubiquitin Proteasome Market, By Reagents and Assay Development, 2014 – 2022, (US$ Mn)
5.1. Reagents
5.1.1. Reagents for Ubiquitin Proteasome Research
5.1.2. Reagents for Ubiquitin Proteasome based Drug Discovery
5.2. Assays
5.2.1. Assays for Ubiquitin Proteasome Research
5.2.2. Assays for Ubiquitin Proteasome based Drug Discovery

6. Global Ubiquitin Proteasome Market, By Geography, 2014 – 2022, (US$ Mn)
6.1. Overview
6.2. North America
6.2.1. North America Ubiquitin Proteasome Market, By Type of Application, 2014 – 2022 (US$ Mn)
6.2.1.1. Drug Discovery
6.2.1.1.1. E1 Ligase
6.2.1.1.2. E2 Ligase
6.2.1.1.3. E3 Ligase
6.2.1.1.4. Deubiquitnases
6.2.1.2. Diagnosis
6.2.1.2.1. Cancer Biomarkers
6.2.1.2.2. Cardiovascular Disease Biomarkers
6.2.1.2.3. Central Nervous System (CNS) Biomarkers
6.2.1.2.4. Others
6.2.2. U.S
6.2.3. Canada
6.3. Europe
6.3.1. Europe Ubiquitin Proteasome Market, By Type of Application, 2014 – 2022 (US$ Mn)
6.3.1.1. Drug Discovery
6.3.1.1.1. E1 Ligase
6.3.1.1.2. E2 Ligase
6.3.1.1.3. E3 Ligase
6.3.1.1.4. Deubiquitnases
6.3.1.2. Diagnosis
6.3.1.2.1. Cancer Biomarkers
6.3.1.2.2. Cardiovascular Disease Biomarkers
6.3.1.2.3. Central Nervous System (CNS) Biomarkers
6.3.1.2.4. Others
6.3.2. U.K
6.3.3. Germany
6.3.4. Rest of Europe
6.4. Asia Pacific
6.4.1. Asia Pacific Ubiquitin Proteasome Market, By Type of Application, 2014 – 2022 (US$ Mn)
6.4.1.1. Drug Discovery
6.4.1.1.1. E1 Ligase
6.4.1.1.2. E2 Ligase
6.4.1.1.3. E3 Ligase
6.4.1.1.4. Deubiquitnases
6.4.1.2. Diagnosis
6.4.1.2.1. Cancer Biomarkers
6.4.1.2.2. Cardiovascular Disease Biomarkers
6.4.1.2.3. Central Nervous System (CNS) Biomarkers
6.4.1.2.4. Others
6.4.2. China
6.4.3. Japan
6.4.4. Rest of Asia Pacific
6.5. Latin America (LATAM)
6.5.1. Latin America Ubiquitin Proteasome Market, By Type of Application, 2014 – 2022 (US$ Mn)
6.5.1.1. Drug Discovery
6.5.1.1.1. E1 Ligase
6.5.1.1.2. E2 Ligase
6.5.1.1.3. E3 Ligase
6.5.1.1.4. Deubiquitnases
6.5.1.2. Diagnosis
6.5.1.2.1. Cancer Biomarkers
6.5.1.2.2. Cardiovascular Disease Biomarkers
6.5.1.2.3. Central Nervous System (CNS) Biomarkers
6.5.1.2.4. Others
6.5.2. Brazil
6.5.3. Mexico
6.5.4. Rest of LATAM
6.6. Middle East and Africa (MEA)
6.6.1. Middle East and Africa Ubiquitin Proteasome Market, By Type of Application, 2014 – 2022 (US$ Mn)
6.6.1.1. Drug Discovery
6.6.1.1.1. E1 Ligase
6.6.1.1.2. E2 Ligase
6.6.1.1.3. E3 Ligase
6.6.1.1.4. Deubiquitnases
6.6.1.2. Diagnosis
6.6.1.2.1. Cancer Biomarkers
6.6.1.2.2. Cardiovascular Disease Biomarkers
6.6.1.2.3. Central Nervous System (CNS) Biomarkers
6.6.1.2.4. Others

7. Profiles
7.1. Acenta Therapeutics
7.2. Aegera Therapeutics Inc. (Subsidiary of Pharmascience Inc.)
7.3. Amgen Inc.
7.4. Biogeneva Corporation
7.5. Celgene Corporation
7.6. Elan Pharmaceutical
7.7. Enzo Lifesciences
7.8. Boston Biochem
7.9. Genentech, Inc.
7.10. Johnson and Johnson
7.11. Life Sensors, Inc.
7.12. Thermo Fischer Scientific
7.13. Onyx Pharmaceuticals, Inc.
7.14. Teva Pharmaceutical Industries Ltd.
7.15. Ubiquigent Ltd.
7.16. Others

Note:

  • This ToC is tentative in nature and is subject to further refinement during the course of the research
  • The list of company profiles included in this ToC is tentative. Profiles of specific players, if required, shall be added to the report upon request
Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +